Carotid Artery Disease
Conditions
Brief summary
The primary objective of this study is to compare the safety and effectiveness of the Cordis Nitinol Carotid Stent and Delivery Systems (5.5 F and 7 F) with the ANGIOGUARD XP distal protective device to CEA in the treatment of carotid artery disease in patients at increased risk for surgery.
Interventions
DEVICECordis Nitinol Stent
DEVICEPRECISE tapered stent
DEVICEANGIOGUARD XP Emboli Capture Guidewire (ECGW)
Sponsors
Cordis US Corp.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. The patient must be \> 18 years of age. 2. The patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, defined as: * one or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or * one or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event), except as excluded below, with stenosis \>50%, (as determined by ultrasound or angiogram) of the common or internal carotid artery, OR The patient must have a \>80% diameter stenosis (as determined by ultrasound or angiogram) of the internal or common carotid artery without neurological symptoms. 3. To be entered into the study, the patient must have one or more of the following conditions: * congestive heart failure (class III/IV) and/or known severe left ventricular dysfunction LVEF \< 30% * open heart surgery within six weeks * recent MI (\>24 hours and \<4 weeks) * unstable angina (CCS class III/IV) * synchronous severe cardiac and carotid disease requiring open heart surgery and carotid revascularization * Age greater than 80 years as a single risk factor.
Exclusion criteria
1. The patient is experiencing an acute ischemic neurologic stroke or has experienced a stroke within the past 48 hours. 2. The patient has an intracranial mass lesion (i.e., abscess, tumor, or infection). 3. The reference segment diameter (distal common carotid and internal carotid artery segment cephalic to the lesion) is less than 4mm or greater than 9mm by quantitative analysis. See Instructions For Use, for proper stent sizing. The exception to this would be with a lesion having \>95% stenosis where the true diameter of the distal vessel can not be determined such as the case with a string sign or distal vessel collapse. In this case the judgment of the interventionalist will prevail with the intention not to oversize the stent to the distal vessel by more than 2mm. 4. The patient has known peripheral vascular, supra-aortic or internal carotid artery tortuosity which preclude the use of catheter-based techniques if so randomized. 5. The patient has any intracranial aneurysm (\> 9 mm).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| composite of major adverse clinical events including death, any stroke, and/or myocardial infarction at 30-days post-procedure | 30-days post-procedure |
| The same 30-day composite of major adverse clinical events plus death and/or ipsilateral stroke between 31-days and 12-months post-procedure. | Between day 31 and 12-months post-procedure. |
Secondary
| Measure | Time frame |
|---|---|
| <30% residual stenosis determined by angiography immediately post-stent placement and post-dilatation | — |
| endovascular access site complications, such as the need for surgical repair or blood transfusion | — |
| surgical site complications, such as wound infection or hematoma, that prolong hospital stay, require incision and drainage, or need blood transfusion | — |
| patency (< 50% restenosis) of the Cordis Nitinol Stent as determined by carotid ultrasound imaging within 48 hours, at six months, and one, two and three years post-procedure | — |
| independent neurologic assessments at 24 + 12 hours, thirty days, six months, and one, two and three years post-procedure (in addition to stroke scales, the development of any cranial nerve deficits will be recorded) - persistent neurologic deficits | — |
| successful stent deployment at the target lesion in a variety of carotid morphologies | — |
| six (6)-month, one (1)-year, two (2)-year and three (3)-year composite of major adverse clinical events including death and ipsilateral stroke | 6 month and 1, 2, 3yr |
| safety assessment of the ANGIOGUARD XP Emboli Capture Guidewire Device | — |
| presence of trapped material as determined by the interventionalist's visual inspection of the ANGIOGUARD XP filter basket following recapture at the completion of the procedure | — |
| laboratory analysis of trapped material contained in the ANGIOGUARD XP filter basket | — |
| thirty (30)-day and six (6)-month evaluation for disabling stroke | Day 30 and 6 months |
| successful filter deployment and retrieval | — |
Outcome results
None listed